Nodality’s Single Cell Network Profiling (SCNP) technology provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology at the single-cell level, creating competitive advantages in addressing many of the most pressing challenges in drug discovery and development for cancer and autoimmune disease. Appointed Ralph Snyderman to BOD, Feb. 2014.